HUMA News and Press, Humacyte Inc.

- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society -  - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term ...

2026-02-09 16:57:42 ET Investment Overview The stock of Durham, North Carolina-based biotech Humacyte, Inc. ( HUMA ) is buoyant today—up ~28% at the time of writing, with a share price of $1.2 and a market cap of $236m—on news that, according to a press relea...

2026-02-09 13:30:29 ET Denve, Colorado- Today’s action is being driven less by macro noise and more by company-specific execution stories, particularly among small- and mid-cap innovators pushing into commercialization, strategic scale, and balance-sheet transformation. Notably, all ...

2026-02-09 12:18:35 ET More on Humacyte Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript Humacyte announces credit facility of $77.5M with Avenue Capital Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise ...

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) ...

- Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte&...

- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel -  - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, I...

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) -  - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-ter...

2025-12-16 08:26:13 ET More on Humacyte Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript Humacyte: Shares Tank On Fundraising News - What You Need To Know Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise ...

DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Oppo...